The latest announcement is out from Oxford BioDynamics ( (GB:OBD) ).
Oxford BioDynamics has expanded its partnership with Bupa UK insurance to include coverage for its EpiSwitch® PSE prostate cancer test. This strategic agreement enhances access to the PSE test for Bupa’s 3.9 million customers, particularly those with raised PSA levels but no high-risk factors or symptoms. The PSE test, known for its high accuracy and positive predictive value, aims to improve early prostate cancer diagnosis and reduce unnecessary procedures, aligning with Bupa’s commitment to advanced cancer care.
More about Oxford BioDynamics
Oxford BioDynamics is a precision clinical diagnostics company that specializes in developing specific and sensitive tests based on its EpiSwitch® 3D genomics platform. The company focuses on bringing advanced precision medicine testing to the medical field.
YTD Price Performance: -68.33%
Average Trading Volume: 21,058,889
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £9.79M
For detailed information about OBD stock, go to TipRanks’ Stock Analysis page.